EUVIMEDEUVIMED entdecken
Open Access

Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children

Montelukast-Anwendung und Risiko neuropsychiatrischer unerwünschter Ereignisse bei Kindern

Viktor Wintzell, Philip Brenner, Linda Halldner, Samuel Rhedin, Tong Gong, Catarina Almqvist

JAMA Pediatrics · 01.04.2025 · 179 (4) · 418

DOI: 10.1001/jamapediatrics.2024.5429 ↗

Auf einen Blick

In einer schwedischen Registerkohortenstudie war Montelukast bei Kindern und Jugendlichen nicht mit einem erhöhten Risiko neuropsychiatrischer unerwünschter Ereignisse verbunden.

Fragestellung

Besteht bei Kindern und Jugendlichen ein Zusammenhang zwischen Montelukast und neuropsychiatrischen unerwünschten Ereignissen?

Methode

Nationwide register-based cohort study aus Schweden von 2007 bis 2021 bei Kindern und Jugendlichen von 6 bis 17 Jahren; Vergleich Montelukast vs LABA; gewichtete Analyse mit pooled logistic regression.

Ergebnisse

Die Inzidenz lag bei 2.39 pro 100 patient-years unter Montelukast und bei 2.41 pro 100 patient-years unter LABA. Für den primären Endpunkt ergab sich ein HR von 0.99 (95 %-KI 0.84-1.16).

Schlussfolgerung der Autor:innen

In dieser großen Studie aus der Routineversorgung bestand kein Zusammenhang zwischen Montelukast und dem Risiko neuropsychiatrischer unerwünschter Ereignisse.

Kernaussagen

  • Kein Zusammenhang zwischen Montelukast und neuropsychiatrischen Ereignissen
  • Primärer Endpunkt: HR 0.99 (95 %-KI 0.84-1.16)
  • Auch für einzelne neuropsychiatrische Endpunkte keine wesentlichen Unterschiede

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Pediatrics, erschienen am 01.04.2025. Verfasst von Viktor Wintzell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Cyclopropanes, Sulfides, Quinolines, Acetates. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.

Objective

To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents. Design, Setting, and Participants This nationwide register-based cohort study used data from Sweden from January 1, 2007, to November 30, 2021. Participants included children aged 6 to 17 years who used montelukast and long-acting β-agonists (LABA). Data analysis was performed from December 2023 to April 2024. Exposure Montelukast vs LABA. Main Outcomes and Measures The primary outcome, any neuropsychiatric adverse event, was a composite of secondary outcomes, including anxiety; depression; sleep-related disorders; suicide and suicidal actions; disrupted control of activity, attention, and behavior; and confusion and psychotic-like symptoms. Outcomes were defined on the basis of diagnosis codes and dispensings of prescription drugs for specific neuropsychiatric symptoms. Patients were followed up from drug initiation to discontinuation, and treatment and censoring weights were used to adjust for potential confounding on baseline and selection bias from informative censoring. Pooled logistic regression was used to estimate hazard ratios (HRs).

Results

The final cohort included 74 291 children (mean [SD] age, 12.3 [3.3] years; 35 446 female [47.7%]); 26 462 used montelukast and 47 829 used LABA. During a mean (SD) follow-up of 5.8 (3.2) months, 310 neuropsychiatric adverse events in the montelukast patients and 566 events in the LABA patients were identified. In the weighted cohort, the incidence rates of neuropsychiatric adverse events were 2.39 per 100 patient-years among the montelukast users and 2.41 per 100 patient-years among the LABA users. This translated to a weighted HR of 0.99 (95% CI, 0.84-1.16). No substantial differences were observed between the montelukast and LABA patients when analyzing the risk of specific neuropsychiatric adverse events: the HRs were 0.79 (95% CI, 0.54-1.14) for anxiety; 1.16 (95% CI, 0.70-1.95) for depression; 0.93 (95% CI, 0.76-1.13) for sleep-related disorders; 1.31 (95% CI, 0.64-2.69) for suicide and suicidal actions; 1.27 (95% CI, 0.84-1.90) for disrupted control of activity, attention, and behavior; and 0.51 (95% CI, 0.05-5.53) for confusion and psychotic-like symptoms. The risk of the primary outcome was consistent over subgroups and a range of sensitivity analyses. Conclusions and Relevance In this large study of children and adolescents based on data from routine clinical practice, there was no association between use of montelukast and the risk of neuropsychiatric adverse events. In aggregation with other robust observational studies, these results can inform the management of asthma and allergic rhinitis in this patient group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclopropanesSulfidesQuinolinesAcetatesMental DisordersAnti-Asthmatic AgentsHumansChildFemaleMaleAdolescentSwedenCohort StudiesAsthmaRegistries

Substanzen

montelukastCyclopropanesSulfidesQuinolinesAcetatesAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Zitieren

APA

Wintzell, V., Brenner, P., Halldner, L., Rhedin, S., Gong, T., & Almqvist, C. (2025). Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children. JAMA Pediatrics, 179(4), 418. https://doi.org/10.1001/jamapediatrics.2024.5429

Vancouver

Wintzell V, Brenner P, Halldner L, Rhedin S, Gong T, Almqvist C. Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children. JAMA Pediatrics. 2025;179(4):418. doi:10.1001/jamapediatrics.2024.5429

BibTeX
@article{Wintzell2025,
  author = {Wintzell, Viktor and Brenner, Philip and Halldner, Linda and Rhedin, Samuel and Gong, Tong and Almqvist, Catarina},
  title = {Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children},
  journal = {JAMA Pediatrics},
  year = {2025},
  volume = {179},
  number = {4},
  pages = {418},
  doi = {10.1001/jamapediatrics.2024.5429}
}
Kostenlos starten →